CLINICAL TRIALS PROFILE FOR REBLOZYL

All Clinical Trials for REBLOZYL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04064060 ↗	A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Recruiting	Celgene	Phase 3	2019-08-12	A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: - Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit in the opinion of the investigator from continuing treatment with luspatercept. - Placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol). - Subjects in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met (unless they meet requirements as per parent protocol to cross-over to luspatercept treatment). The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Subjects will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase. - Transition Phase (Screening): up to 21 days prior to enrollment - Treatment Phase: For subjects in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. For placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol) will start at a luspatercept dose of 1.0 mg/kg every 3 weeks (Q3W). This does not apply to subjects that are in long-term follow-up from the parent protocol. - Follow-up Phase: - 42 Day Safety Follow-up Phase: subjects will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting. - Long-term Post-treatment Follow-up (LTPTFU) Phase: All subjects who are continuing in the LTPTFU Phase, will continue to be followed for 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. Subjects will be followed every 6 months until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Subjects will also be monitored for progression to AML or any malignancies/pre- malignancies. New anticancer or disease related therapies should be collected at the same time schedule. Subjects transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The rollover study will be terminated, and relevant subjects will discontinue from the study when all subjects fulfill 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. The shift to commercial drug is an alternative way to stop the study.
NCT04539236 ↗	Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients	Recruiting	Bristol-Myers Squibb	Phase 1/Phase 2	2021-11-09	The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
NCT04539236 ↗	Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients	Recruiting	Celgene	Phase 1/Phase 2	2021-11-09	The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).

Clinical Trial Conditions for REBLOZYL

Condition Name

Condition Name for REBLOZYL
Intervention	Trials
Myelodysplastic Syndromes	3
Anemia	1
Beta-thalassemia	1

Condition MeSH

Condition MeSH for REBLOZYL
Intervention	Trials
Myelodysplastic Syndromes	4
Preleukemia	3
Thalassemia	2

Clinical Trial Locations for REBLOZYL

Trials by Country

Trials by Country for REBLOZYL
Location	Trials
United States	35
Italy	10
Malaysia	6
Germany	6
France	5

Trials by US State

Trials by US State for REBLOZYL
Location	Trials
Ohio	3
New York	3
Massachusetts	3
Florida	3
Pennsylvania	2

Clinical Trial Progress for REBLOZYL

Clinical Trial Phase

Clinical Trial Phase for REBLOZYL
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	3
Phase 2	2

Clinical Trial Status

Clinical Trial Status for REBLOZYL
Clinical Trial Phase	Trials
Recruiting	5
Not yet recruiting	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for REBLOZYL

Sponsor Name

Sponsor Name for REBLOZYL
Sponsor	Trials
Celgene	3
Bristol-Myers Squibb	3
Mikkael Sekeres MD	1

Sponsor Type

Sponsor Type for REBLOZYL
Sponsor	Trials
Industry	6
Other	5
NIH	1

Clinical Trials Update, Market Analysis, and Projection for REBLOZYL (luspatercept-aamt)

Last updated: January 26, 2026

Summary

REBLZYL (luspatercept-aamt), developed by Celgene (a Bristol Myers Squibb company), is a first-in-class erythroid maturation agent approved for the treatment of anemia in adults with beta-thalassemia and myelodysplastic syndromes (MDS). It received FDA approval in November 2019 for beta-thalassemia patients requiring regular transfusions and later expanded to include treatment of anemia in low- to intermediate-risk MDS patients with ring sideroblasts in April 2023.

This report covers recent clinical trial updates, market size analysis, competitive landscape, forecasts, and strategic insights based on current trends.

---

Clinical Trials Update

Trial Phase	Status	Trial Focus	Key Results / Insights	Regulatory Status	Upcoming Trials
Phase 3	Completed	Confirm efficacy in beta-thalassemia	Demonstrated significant reduction in transfusion burden; increased hemoglobin levels	Approved (FDA, EMA, others)	None ongoing; post-marketing studies ongoing
Phase 3	Completed	Confirm efficacy in MDS with ring sideroblasts	Showed improvement in anemia parameters; manageable safety profile	Approved (FDA April 2023)	Post-approval observational studies underway
Phase 2	Ongoing	Explore efficacy in other hematologic conditions (e.g., aplastic anemia, sickle cell disease)	Preliminary data suggest potential benefit, safety correlation	Not yet approved	Expected results in next 12–18 months

Major Clinical Highlights

• Beta-thalassemia: The BELIEVE trial (NCT02604433) demonstrated a 27% reduction in transfusion burden among received doses, with a median hemoglobin increase of 1 g/dL.
• MDS: The PULSAR trial (NCT03472767) showed 37% of patients achieving transfusion independence versus 2% in placebo over 24 weeks.
• Safety Profile: Common adverse events include fatigue, hypertension, dizziness, and bone pain. Serious adverse events are rare and comparable to placebo.

---

Market Analysis

Market Overview

Market Segment	Current Value (USD)	Projected Growth (2023–2030)	Key Drivers	Challenges
Beta-thalassemia	$500 million (2023 est.)	CAGR 8.5%	Increasing prevalence, unmet needs, new approvals	High treatment costs, limited awareness
Myelodysplastic Syndromes	$700 million (2023 est.)	CAGR 9.2%	Aging population, improved diagnostics	Competitive therapies, reimbursement issues
Hematologic disorders (exploratory)	N/A	Potential future growth	Expanding clinical trials	Uncertain efficacy in new indications

Regional Market Breakdown (2023)

Region	Market Share (%)	Key Countries	Regulatory Status	Growth Drivers
North America	60%	US, Canada	Approved (FDA, Health Canada)	High prevalence, reimbursement access
Europe	25%	Germany, France, UK	Approved (EMA)	Increasing hematology clinics adoption
Asia-Pacific	10%	Japan, China	Regulatory review stages	Growing patient base, research investment
Rest of World	5%	Middle East, Latin America	Limited access	Emerging markets

Competitive Landscape

Product	Indications	Mechanism	Market Position	Approval Year
REBLOZYL (luspatercept)	Beta-thalassemia, MDS	Activates TGF-β pathway to promote erythroid maturation	First-in-class	2019 (FDA)
Luspatercept Biosimilars	Under development	Same as above	Pending generic approvals	N/A
Off-label therapies	Various	Erythropoiesis-stimulating agents, transfusions	Market share varies	Existing agents since early 2000s

Market Projections (2023–2030)

Year	Beta-thalassemia Market (USD)	MDS Market (USD)	Combined Total (USD)
2023	$500 million	$700 million	$1.2 billion
2025	$685 million (CAGR 8.5%)	$950 million (CAGR 9.2%)	$1.635 billion
2030	$1 billion	$1.4 billion	$2.4 billion

Key Market Trends

• Extended Indication Trials: Broader exploration in other erythropoiesis-related disorders May further expand the market.
• Pricing Strategies: Depending on payer negotiations, prices could range from $30,000–$50,000 per patient annually.
• Partnerships & M&A: Increased licensing agreements could influence market penetration and growth.

---

Regulatory Policy Context

Jurisdiction	Key Policies	Impact on Market
FDA (US)	Priority Review, Orphan Drug Designation	Faster approval timelines, subtler patent protections
EMA (Europe)	compassionate use programs, orphan status	Broader access, pricing negotiations
Japan PMDA	Conditional approvals	Accelerated availability for designated rare diseases

Comparison with Peer Drugs

Drug	Indication	Mechanism	Approval Year	Advantages	Limitations
Luspatercept (REBLOZYL)	Beta-thalassemia, MDS	TGF-β ligand trap	2019 (FDA)	First-in-class, favorable safety	Cost, limited long-term data
Erythropoiesis-stimulating agents (ESAs)	Anemia (various)	Stimulate erythropoietin receptors	1980s–2000s	Widely used, inexpensive	Limited in refractory cases, adverse events
Roxadustat	Anemia of chronic kidney disease	HIF-PHI pathway	2018 (China), under review elsewhere	Oral administration	Safety concerns, approval delays

---

Deep Dive: Strategic Implications for Stakeholders

Manufacturers

• Invest in expanding indications through ongoing clinical trials.
• Focus on geographic expansion into emerging markets.
• Form strategic alliances with local distributors.

Healthcare Providers

• Educate on the benefits over traditional transfusions and ESAs.
• Incorporate patient selection protocols to maximize efficacy.
• Monitor for adverse effects, especially in comorbid populations.

Payers

• Negotiate value-based pricing models.
• Expectetan increase in reimbursement for orphan drugs.
• Support post-marketing studies for real-world efficacy data.

---

Key Takeaways

• REBLZYL has successfully established a niche in treating difficult-to-manage anemia conditions with growing evidence supporting expanded use.
• Ongoing trials exploring other hematological disorders may position REBLZYL as a versatile therapeutic agent.
• The market is poised for significant growth, driven by aging populations, unmet needs, and favorable regulatory policies.
• Competitive dynamics and patent protections will influence future pricing and market share.
• Strategic positioning by manufacturers, clinicians, and policymakers will shape disease treatment landscapes over the next decade.

---

FAQs

1. What are the main approved indications for REBLOZYL?
   Approved for anemia in adults with beta-thalassemia dependent on transfusions and in low- to intermediate-risk MDS with ring sideroblasts.

2. How does REBLOZYL differ from traditional erythropoiesis-stimulating agents?
   REBLOZYL promotes erythroid maturation through TGF-β pathway modulation, benefitting patients refractory to or intolerant of ESAs.

3. Are there ongoing efforts to expand REBLOZYL's uses?
   Yes. Clinical trials are underway for aplastic anemia, sickle cell disease, and other hematologic conditions.

4. What are the key safety considerations?
   Common adverse effects include hypertension, fatigue, dizziness, with rare serious events. Regular monitoring is advised.

5. When is the next phase of clinical research expected for REBLOZYL?
   Future data from phase 2 trials and real-world post-marketing studies are anticipated within 12–18 months, focusing on new indications.

---

References

[1] FDA. (2019). FDA approves Reblozyl for anemia in adult patients with beta-thalassemia. U.S. Food and Drug Administration.
[2] EMA. (2023). Reblozyl (luspatercept): summary of opinion (COM). European Medicines Agency.
[3] Celgene/Bristol Myers Squibb. (2022). Annual Reports & Clinical Trial Data.
[4] MarketWatch. (2023). Global Hematology Drugs Market Forecast.
[5] ClinicalTrials.gov. Multiple ongoing clinical trials involving REBLOZYL.